宫颈癌中EGFR蛋白表达及其临床病理意义  

Expression of EGFR in cervical cancer and its relation to clinicopathology

作　　者：黄必飞 王超群 赵永明 孙鑫鑫 王倩 陈艳 吴爱姣 曾悦 吴丹丹 王艳 

机构地区：[1]东阳市人民医院病理科,322100 [2]东阳市人民医院肿瘤外科,322100 [3]东阳市人民医院肿瘤内科,322100

出　　处：《浙江医学》2016年第2期99-101,共3页Zhejiang Medical Journal

基　　金：浙江省金华市科技计划重点项目(2012-3-021);浙江省医药卫生科技计划项目(2012KYB230);浙江省金华市科技计划项目(2013-3-097)

摘　　要：目的探讨表皮生长因子受体1（EGFR）蛋白表达在宫颈癌发生、发展中的临床病理意义。方法采用免疫组化EnVision法检测120例宫颈癌组织、49例高级别上皮内瘤变（CIN2～3）、40例低级别上皮内瘤变（CIN1）、37例正常宫颈组织中EGFR蛋白的表达，并进行比较分析。结果（1）正常宫颈、CIN1、CIN2-3宫颈癌组织中EGFR蛋白表达阳性率分别为10．8％（4／37）、125％（5／40）、42．9％（21／49）、892％（107／120）。宫颈癌组织中EGFR蛋白表达阳性率显著高于CIN2-3、CIN1及正常宫颈组织（均P〈0.01）；EGFR蛋白在CIN2-3中表达显著高于CIN，和正常宫颈组织（均P〈0．01）；CIN1和正常宫颈组织之间EGFR蛋白表达阳性率无统计学差异（P〉0．05）。（2）肿瘤浸润深度更深的宫颈癌患者宫颈癌组织中EGFR蛋白表达阳性率高于浸润深度较浅的患者（P〈0．01）。结论EGFR在宫颈癌进展过程中起了重要作用，有望成为抗宫颈癌治疗的一个潜在生物学标志。Objective To investigate the expression of epidermal growth factor receptor 1 （EGFR） in cervical cancer and to evaluate its clinicopathological significance. Methods The immunohistochemical EnVision method was used to evaluate the expression of EGFR in 120 cases of cervical cancer, 49 cases of high-grade intraepithelial neoplasia （CIN2-3）, 40 cases of low-grade intraepithelial neoplasia （CIN1） and 37 cases of normal cervical tissues. Results EGFR protein expression rates in normal cervical tissues, CIN1, CIN2-3 and cervical cancer were 10.8% （4/37）, 12.5%（5/40）, 42.9% （21/49） and 89.2% （107/120）, respectively. The EGFR positive rate in cervical cancer was significantly higher than those in CIN〉3, CIN1 and normal cervical tissues（P〈0.01）; and the positive rate in CIN2-3 was significantly higher than those in CIN1 and normal cervical tissues（P〈0.01）; but there was no significant difference between normal cervical tissue and CIN1 （P 〉0.05）. EGFR protein positive rate was higher in patients with deeper invasion of cervical carcinoma（P〈0.01）. Conclusion Results indicates that EGFR may play an important role in the development of cervical cancer and it may become a potential target for anti-cancer therapy.

关 键 词：EGFR 宫颈癌 免疫组化 

分 类 号：R737.33[医药卫生—肿瘤]